



News Release

Contact: Ronald Trahan, APR, Ronald Trahan Associates Inc., 508-359-4005, x108

Corindus Vascular Robotics closes \$9 million “Series C” round of financing

Proceeds will be used to seek regulatory clearances for initial application of its *CorPath*[™] platform in the cath lab: percutaneous coronary intervention (PCI)

NATICK, Mass., Nov. 18, 2009—**Corindus Vascular Robotics** announced today that it has closed a **\$9 million “Series C”** round of financing. Principal investors included **HealthCor® Partners** and **20/20 HealthCare Partners**. Proceeds will be used primarily to seek regulatory clearances for its initial product: the **CorPath[™]** system for robotic percutaneous coronary intervention (PCI).

Percutaneous coronary intervention (PCI), commonly known as ‘coronary angioplasty’ or simply ‘angioplasty’, is a procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist in a cath lab utilizing x-ray angiography imaging—which exposes physicians to significant occupational hazards, including radiation exposure as well as chronic orthopedic ailments and fatigue due to the required use of heavy lead protection garments.

“There are many published studies which show that the cath lab is a *hazardous* work environment, where physicians are being exposed to increased risk of not only cancer but also spinal problems,” said **David M. Handler**, President and CEO of Corindus. “Our CorPath system is designed to significantly reduce radiation exposure, physician fatigue and other occupational hazards to physicians by allowing him or her to operate in an ergonomically correct position while shielded from harmful and repeated radiation exposure,” added Handler. “The closing of our Series C financing now enables Corindus to seek regulatory clearances for the initial application of our CorPath platform for the cath lab: PCI.”

About Corindus Vascular Robotics

Corindus designs, manufactures and commercializes precision vascular robotic systems for use in minimally invasive procedures. The Company’s disposable medical device business model is enabled by a simple and low-cost console. The Company’s initial product, the **CorPath[™]** system, is the world’s first to precisely drive coronary guidewires and stent/balloon catheters during percutaneous coronary intervention (PCI) procedures performed in a cath lab. While Corindus is focused initially on PCIs, its open-platform technology and IP allow the Company to address other segments of the vascular market—including peripheral and other complex cardiac interventions such as structural heart disease repair.

#####

NOTE: The Corindus *CorPath*[™] system is an investigational device and limited by federal law to investigational use only.